4.8 Editorial Material

A role for microRNA in cystic liver and kidney diseases

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 118, Issue 11, Pages 3585-3587

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI36870

Keywords

-

Funding

  1. NICHD NIH HHS [K12HD000850, K12 HD000850] Funding Source: Medline
  2. NIDDK NIH HHS [R03 DK081450, R01 DK079881, R03DK081450, K08DK070881, K08 DK070881] Funding Source: Medline

Ask authors/readers for more resources

The polycystic liver and kidney diseases are a family of disorders with heterogeneous etiologies. Proposed mechanisms of disease include ciliary dysfunction, excess cell proliferation, and altered cell-cell or cell-matrix interactions. In this issue of the JCI, Lee and colleagues provide data to support a novel mechanism for cystogenesis involving microRNA (miRNA) (see the related article beginning on page 3714). They demonstrate that levels of the miRNA miR15a are decreased in livers of patients with autosomal recessive and autosomal dominant polycystic kidney disease (ARPKD and ADPKD, respectively) and congenital hepatic fibrosis as wen as in the PKC rat model of ARPKD. This results in increased expression of the cell-cycle regulator Cdc25A, which is a direct target of miR15a, and increased cellular proliferation and cystogenesis in vitro. These findings suggest that other miRNAs may also participate in the molecular pathogenesis of cystic liver and kidney diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available